Study of RN1701 for aggressive B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This phase 1 trial tests an investigational treatment called RN1701 for people with certain types of B-cell lymphoma that have come back or not responded to previous therapies. The goal is to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must be between 18 and 75 years old.
- Diagnosed with a type of B-cell lymphoma, like large B-cell, follicular, mantle-cell, or transformed lymphoma, that is CD19 or CD20 positive.
- Your lymphoma must have come back or not responded to at least two prior treatments, including a stem cell transplant or CAR-T therapy in some cases.
- Must have at least one tumor that can be measured by scan (more than 1.5 cm in lymph nodes or 1.0 cm elsewhere).
- Must have adequate organ function (kidney, liver, blood counts) and a life expectancy of at least 3 months.
- Must not have active serious infections, certain heart problems, or central nervous system involvement of lymphoma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called RN1701 for people with certain types of B-cell lymphoma that have come back or not responded to prior treatments. It aims to see if the drug is safe and effective.
This early-stage trial tests a new injection called RN1701 for B-cell lymphomas (blood cancers) that have not responded to or have returned after prior treatments. The study aims to see if this therapy can help patients whose cancer is difficult to treat.
This trial tests a new immunotherapy, RN1201, for people with certain blood cancers (like multiple myeloma, leukemia, or lymphoma) that have come back or not responded to standard treatments. It aims to see if this treatment can help when other options have stopped working.
This study looks at a new way to treat B-cell blood cancers that have not responded to other treatments or have come back. It tests a therapy that targets cancer cells using RNA, which is a molecule that helps make proteins in your body.
This trial tests a new treatment using specially engineered immune cells from a healthy donor to fight certain B-cell blood cancers that have come back or not responded to standard therapy. It aims to see if these cells can safely help patients achieve remission.
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
Hear when a new Relapsed/Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.